REPLIMUNE GROUP, INC. Long-Term Debt, Maturity, Year Two
REPLIMUNE GROUP, INC. (REPL) had Long-Term Debt, Maturity, Year Two of $5.72 million as of 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2020-11-05
- 2020-09-30: Long-Term Debt, Maturity, Year Two $5.72M.
- 2020-06-30: Long-Term Debt, Maturity, Year Two $5.72M.
- 2020-03-31: Long-Term Debt, Maturity, Year Two $527.00K.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2020-09-30 | $5.72M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $5.72M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $527.00K 10-K · filed 2020-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |